Bristol-Myers Squibb (NYSE:BMY) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Bristol-Myers Squibb (NYSE:BMY) have been given an average recommendation of “Buy” by the eighteen brokerages that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $72.50.

Several research firms have recently commented on BMY. Truist Financial raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, April 13th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $62.00 price objective on shares of Bristol-Myers Squibb in a research note on Thursday, May 6th. Truist Securities raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price objective for the company from $66.00 to $74.00 in a research note on Tuesday, April 13th. Truist raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Finally, Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research note on Tuesday, April 6th.

In other news, EVP Rupert Vessey sold 30,546 shares of the firm’s stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $64.29, for a total transaction of $1,963,802.34. Following the sale, the executive vice president now owns 45,139 shares in the company, valued at $2,901,986.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Adam Dubow sold 3,119 shares of the firm’s stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $64.21, for a total value of $200,270.99. Following the sale, the senior vice president now owns 16,243 shares in the company, valued at approximately $1,042,963.03. The disclosure for this sale can be found here. Insiders have sold 74,783 shares of company stock worth $4,770,493 in the last 90 days. Insiders own 0.11% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Retirement Group LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $27,000. Orion Capital Management LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Perennial Advisors LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $29,000. Brand Asset Management Group Inc. acquired a new position in Bristol-Myers Squibb in the first quarter valued at $31,000. Finally, Alpha DNA Investment Management LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 71.75% of the company’s stock.

Bristol-Myers Squibb stock opened at $67.27 on Friday. The company has a quick ratio of 1.45, a current ratio of 1.56 and a debt-to-equity ratio of 1.18. The stock’s 50 day moving average is $64.84. The firm has a market cap of $150.20 billion, a PE ratio of -24.24, a price-to-earnings-growth ratio of 1.25 and a beta of 0.64. Bristol-Myers Squibb has a twelve month low of $54.07 and a twelve month high of $67.96.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Wednesday, April 28th. The biopharmaceutical company reported $1.74 EPS for the quarter, missing the consensus estimate of $1.82 by ($0.08). The business had revenue of $11.07 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a negative net margin of 14.53% and a positive return on equity of 33.76%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.72 earnings per share. As a group, equities analysts predict that Bristol-Myers Squibb will post 7.45 EPS for the current year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Recommended Story: Why do analysts give a neutral rating?

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.